ADMA Biologics Inc vs Broadcom Inc — how do they compare? ADMA Biologics Inc trades at $9.87 (market cap $2.22B), while Broadcom Inc trades at $423 (market cap $1.98T). The key difference: Broadcom Inc is far larger — about 891.9× ADMA Biologics Inc's market cap, and Broadcom Inc pays a 0.62% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | AVGO | |
|---|---|---|
Market Cap | $2.22B | $1.98T |
Sector | Health | Technology |
52-Week High | $20.38 | $481.57 |
52-Week Low | $7.60 | $289.60 |
Enterprise Value | $2.29B | $2.02T |
Dividend Yield | — | 0.62% |
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →Broadcom--the combined entity of Broadcom and Avago--boasts a highly diverse product portfolio across an array of end markets. Avago focused primarily on radio frequency filters and amplifiers used in high-end smartphones, such as the Apple iPhone and Samsung Galaxy devices, in addition to an assortment of solutions for wired infrastructure, enterprise storage, and industrial end markets. Legacy Broadcom targeted networking semiconductors, such as switch and physical layer chips, broadband products (such as television set-top box processors), and connectivity chips that handle standards such as Wi-Fi and Bluetooth. The company has acquired Brocade, CA Technologies, Symantec's enterprise security business, and has a pending deal to acquire VMware to bolster its offerings in software.
Read more on AVGO →